Kymera Therapeutics (KYMR) Asset Utilization Ratio (2020 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Asset Utilization Ratio of 0.03 for Q1 2026, down 51.41% year-over-year from 0.06 in Q1 2025, and up 9.46% quarter-over-quarter from 0.03 in Q4 2025.
Kymera Therapeutics (KYMR) Asset Utilization Ratio (2020 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Asset Utilization Ratio for 7 consecutive years, with 0.03 the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Utilization Ratio fell 51.41% year-over-year to 0.03; the TTM figure through Mar 2026 stood at 0.03 (down 51.41% YoY), while the FY2025 annual figure was 0.03, down 52.43% from the prior year.
- Asset Utilization Ratio rose to 0.03 in Q1 2026 per KYMR's latest filing, from 0.03 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.14 in Q4 2023 and bottomed at 0.03 in Q4 2025.
- Historically, Asset Utilization Ratio has averaged 0.08 across 5 years, with a median of 0.08 in 2022.
- Annual changes were most pronounced in 2023 — Asset Utilization Ratio soared 84.72% — and 2024, when it sank 66.43%.
- Kymera Therapeutics' Asset Utilization Ratio stood at 0.08 in 2022, then jumped by 84.72% to 0.14 in 2023, then tumbled by 66.43% to 0.05 in 2024, then tumbled by 41.06% to 0.03 in 2025, then rose by 9.46% to 0.03 in 2026.
- Business Quant data shows KYMR's Asset Utilization Ratio at 0.03 in Q1 2026, 0.03 in Q4 2025, and 0.04 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 0.06 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.06 |
| Mar 31, 2026 | 0.03 |
| Dec 31, 2025 | 0.03 |
| Sep 30, 2025 | 0.04 |
| Jun 30, 2025 | 0.04 |
| Mar 31, 2025 | 0.06 |
| Dec 31, 2024 | 0.05 |
| Sep 30, 2024 | 0.09 |
| Jun 30, 2024 | 0.10 |
| Mar 31, 2024 | 0.11 |
| Dec 31, 2023 | 0.14 |
| Sep 30, 2023 | 0.08 |
| Jun 30, 2023 | 0.09 |
| Mar 31, 2023 | 0.08 |
| Dec 31, 2022 | 0.08 |
| Sep 30, 2022 | 0.08 |
| Jun 30, 2022 | 0.10 |
| Mar 31, 2022 | 0.11 |
| Dec 31, 2021 | 0.12 |
| Sep 30, 2021 | 0.13 |